Phenibut Products and Withdrawal Risks in Columbus, GA

Understand FDA concerns about phenibut products and what original case reports describe about dependence and withdrawal, with evidence limits in Columbus, GA.

An adult seated at a table with a closed notebook and pen.

A product sold as a dietary supplement can still carry serious health risks. FDA’s April 2026 alert identifies unlawful or undeclared ingredients in two specific Addall products, including phenibut in the orange-flavored Addall XR Shot. Separately, two original clinical reports describe dependence or withdrawal in individual patients who used phenibut. These are different kinds of evidence: a product safety alert and detailed accounts of clinical care. Together, they support taking concerns seriously, but they do not establish how often withdrawal occurs or predict what will happen to a particular person.

What did FDA find in the named products?

FDA found different ingredient problems in the two named products, so the findings should not be treated as interchangeable. Its Addall product safety alert identifies phenibut in the orange-flavored shot, not in the capsule findings. For adults considering local care, River City Recovery’s outpatient overview and its admissions information explain available services rather than establish whether a particular product is safe.

FDA tested samples purchased through online retail channels. The orange-flavored Addall XR Shot contained phenibut, which FDA describes as an unlawful ingredient in dietary supplements, and undeclared 1,4-DMAA. Addall XL 30 capsules contained DMHA, also described as unlawful in dietary supplements, and undeclared 1,4-DMAA. The alert says these products were distributed online and through retail locations such as gas stations and convenience stores nationwide. Retail availability does not cancel the concerns identified through testing.

EvidenceReported findingImportant boundary
Orange-flavored Addall XR ShotPhenibut and undeclared 1,4-DMAAThe finding concerns the product identified in FDA’s alert.
Addall XL 30 capsulesDMHA and undeclared 1,4-DMAAFDA did not identify phenibut in its reported capsule findings.
Original clinical case reportsIndividual experiences of dependence or withdrawal associated with phenibutThe reports do not establish population-wide risk or a standard treatment.

The alert distinguishes ingredient-related concerns. FDA says DMAA and DMHA can elevate blood pressure and contribute to cardiovascular problems, including shortness of breath, chest tightening, and heart attack. For phenibut, it identifies poor balance, fatigue, diminished or lost consciousness, potential addiction, and withdrawal after consumption stops. FDA also warns that consuming phenibut with other substances, whether prescribed or illicit, can lead to life-threatening complications. These warnings should not be collapsed into a claim that every symptom comes from the same ingredient.

FDA recommends that consumers stop using and discard the named products, and that retailers and distributors not sell or distribute them. It directs people who become ill after consumption to contact a healthcare provider immediately. This public-health recommendation is not an individualized withdrawal plan. Someone concerned about repeated phenibut use or symptoms needs medical guidance, not an improvised replacement strategy. The alert also does not establish the contents of every other product marketed with phenibut.

What did the 2013 dependence report document?

The 2013 report describes one person who developed difficulty stopping phenibut, withdrawal symptoms, and disruption at work and home. That combination illustrates why understanding the person matters alongside identifying the substance. River City Recovery’s guide to an individualized addiction treatment plan explains how health, substance use, goals, and circumstances shape care; its admissions overview describes assessment without promising a particular treatment.

In the original report, “Phenibut dependence,” the patient had purchased phenibut online to manage anxiety, low mood, and cravings for alcohol. He described initial benefit, followed by dependence. Attempts to reduce his use brought heightened anxiety, anger, and irritability. He reported feeling hostile toward colleagues and relatives and isolating himself to avoid losing his temper. These details show that the concern involved everyday functioning, not simply the fact that he had used a psychoactive substance.

His history was complex. He had previously used alcohol and other substances and was also using kratom when assessed. The clinicians confirmed the presence of phenibut and kratom in samples submitted to their laboratory. They also noted that, at the initial assessment, they could not clearly distinguish primary mood and anxiety disorders from substance-induced symptoms. That uncertainty is important: the report does not justify assigning every emotional symptom to phenibut or assuming an underlying diagnosis from symptoms alone.

The patient sought clinical help because he could not stop the supplements on his own and wanted attention to longstanding anxiety and depression. His care involved prescription treatment, repeated follow-up, and attention to symptoms as they changed. At discharge, the authors reported remission from phenibut dependence and no problematic mood or anxiety symptoms. That was an observed outcome for this patient, not proof that the same treatment would produce the same result for someone else.

The report supports a clear but limited conclusion: phenibut dependence with meaningful withdrawal symptoms and functional consequences occurred in this individual. His earlier perception that the product helped did not prevent later difficulties. However, the account cannot show how common that progression is, which users are most vulnerable, or whether his other substance use and mental health history affected the course.

What happened in the 2017 intoxication and withdrawal report?

The 2017 report describes a more acute presentation involving dissociation followed by severe confusion and agitation during hospitalization. It demonstrates a possible serious course, not the expected course for everyone. River City Recovery’s outpatient care information distinguishes ongoing services from referral needs, while its individualized treatment planning guide explains why immediate medical safety and longer-term care are different decisions.

In “Dissociative intoxication and prolonged withdrawal associated with phenibut: a case report,” a patient arrived at an emergency department after a suicide attempt. He described a dream-like, out-of-body experience, substantial sleep loss, and increased phenibut use before admission. He also reported nonmedical anabolic steroid use. The authors described the presentation as phenibut intoxication followed by prolonged withdrawal, while acknowledging that the additional exposure might have influenced the symptoms or vulnerability.

After initial medical care, the patient briefly appeared more organized. During psychiatric hospitalization, however, he developed worsening insomnia, disorientation, delusions, hallucinations, and agitation. His treatment changed as clinicians observed his response. The report describes improvement in sleep and organization during inpatient care, followed by recovery of orientation and resolution of reported hallucinations. Initial improvement therefore did not mark the end of the illness in this particular case.

The authors explicitly noted important uncertainties. They could not verify the purity of the phenibut used, and they had no blood or urine studies confirming the amount of phenibut exposure. Routine emergency testing was reported as normal or negative in several respects, but that did not provide a direct measurement of phenibut. The report does not establish that a routine drug screen can confirm or exclude phenibut involvement, and it does not support a claim about specialty testing at River City Recovery.

This account matters because it documents an observed severe presentation and the need for continued clinical attention. It should not be used to predict that another person will experience delirium, require hospitalization, or recover on the same timeline. The patient’s reported exposure, sleep deprivation, other substance history, and changing clinical condition all belong to the interpretation. A brief symptom checklist cannot reproduce the assessment that occurred in the hospital.

What can these reports tell you about withdrawal risk?

The reports show that dependence and serious withdrawal presentations can occur, but they cannot measure an individual’s probability of experiencing them. That distinction supports assessment rather than prediction from anecdotes. The guide to individualized addiction care describes matching care to identified needs, and the admissions process explains that recommendations depend on information gathered rather than a website description alone.

A case report provides depth about an individual, including the history, observed symptoms, treatment decisions, and reported outcome. It does not supply a representative sample of everyone who used the substance. Two reports can document different presentations without establishing how frequently either presentation occurs. They also cannot reliably separate every possible contribution from other substances, sleep loss, preexisting symptoms, or uncertain product contents.

  • Dependence is not the same as an acute adverse effect. The 2013 report describes an ongoing pattern involving difficulty stopping and impairment, not only symptoms after a single exposure.
  • Intoxication and withdrawal are not interchangeable labels. The 2017 authors described an initial intoxication presentation and a subsequent withdrawal course during hospitalization.
  • A reported symptom is not a diagnosis. Anxiety, irritability, or poor sleep alone cannot establish phenibut withdrawal or exclude another cause.
  • An observed treatment response is not a general treatment rule. Neither report establishes a standard approach appropriate for every patient.

FDA’s warning adds a separate kind of information. It identifies potential addiction, possibly after only a few uses, and withdrawal following cessation. That warning deserves attention, but it is not a reliable countdown for an individual. Neither the alert nor these two reports provides a way to calculate a safe number of uses or predict exactly when symptoms will begin. Such numbers would imply certainty that the evidence does not provide.

The treatment details in the clinical reports also should not be converted into a home withdrawal plan. Clinicians made decisions in the context of histories, examinations, monitoring, and changing symptoms. A medicine used in one account is not automatically appropriate for another person. The reports do not establish comparative treatment effectiveness, and the favorable elements of one outcome do not erase the uncertainties surrounding treatment selection.

When should someone seek evaluation in Columbus, GA?

Illness after using the products named in FDA’s alert warrants immediate contact with a healthcare provider, and a medical emergency requires emergency help. For nonemergency questions about ongoing care in Columbus, GA, River City Recovery admissions can discuss assessment and available options. Its outpatient treatment overview states that detox referrals are available when needed; it does not establish a specialty phenibut withdrawal service.

Repeated use, difficulty stopping, or symptoms associated with a change in use are reasons to describe the full situation to a qualified healthcare professional. The two reports show why that conversation should include more than the product name. Other substances, prescribed medicines, sleep changes, mental health symptoms, and effects on daily life may all be relevant. A person does not need to decide whether the problem is dependence, intoxication, withdrawal, or another condition before asking for evaluation.

  • Describe the product accurately. Share the name and available label information rather than assuming that all similarly marketed products contain the same ingredients.
  • Explain the pattern and symptoms. Describe repeated use, recent changes, difficulty stopping, and what has changed in sleep, mood, awareness, or functioning.
  • Include other exposures. Tell the clinician about alcohol, prescribed medicines, supplements, and other substances rather than presenting phenibut as the only possible factor.
  • Ask about the appropriate setting. Clarify whether medical evaluation, emergency care, or a different service is needed before routine outpatient planning.

River City Recovery provides adult outpatient care in Columbus, GA. Its admissions information describes clinical and medical assessment, care coordination, and referrals when another setting is indicated. Calling does not guarantee admission or determine that outpatient care is safe. The published facility hours are Monday through Friday, 9:00 AM to 5:00 PM, with weekend closure; those hours should not be interpreted as around-the-clock emergency availability.

For loved ones, useful support can begin with describing observed changes without blame and helping the adult connect with appropriate care. General admissions questions can be asked without making treatment decisions for another adult. The immediate priority is an appropriate response to current symptoms. Longer-term planning can then consider the person’s substance use, health, preferences, and practical circumstances.

Frequently asked questions

What did FDA say about the products in its phenibut alert?

FDA warned against consuming, selling, or distributing orange-flavored Addall XR Shot and Addall XL 30 capsules. Testing found phenibut and undeclared 1,4-DMAA in the shot, while the capsules contained DMHA and undeclared 1,4-DMAA. FDA described serious health risks and advised people who become ill after consumption to contact a healthcare provider immediately.

What do the original clinical reports describe?

The 2013 report describes one patient with phenibut dependence, difficulty stopping, withdrawal symptoms, and disruption at work and home. The 2017 report describes another patient with dissociative intoxication followed by severe withdrawal symptoms during hospitalization. Both accounts include complex individual circumstances and clinical treatment; neither establishes how commonly these experiences occur.

Can case reports predict a person’s withdrawal course?

No. Case reports document what happened to particular individuals, not a representative group of everyone who uses phenibut. Product contents, other substances, health history, and clinical circumstances may differ. These reports cannot reliably predict symptom severity, timing, duration, or the appropriate care setting for another person. Those questions require an individualized medical assessment.

Why do these reports not provide a home withdrawal plan?

The reported treatments occurred with clinical assessment, follow-up, or hospital monitoring, and decisions changed with each patient’s condition. A treatment used in one case is not automatically safe or appropriate for another person. The reports do not establish a standardized withdrawal protocol. Withdrawal concerns need professional evaluation, while emergencies require emergency care rather than routine admissions.

Explore related information from River City Recovery

Contact River City Recovery